ProPhase Labs Inc. (PRPH) Company Profile - Business Overview, Management Team & Corporate Information - Stocknear

ProPhase Labs Inc.

NASDAQ: PRPH · Real-Time Price · USD
0.34
-0.02 (-5.03%)
At close: Jun 09, 2025, 3:59 PM

Company Description

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States.

The company operates in two segments, Diagnostic Services and Consumer Products.

It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.

The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services.

It serves national chain drug, internet-based, and various regional retailers.

The company was formerly known as The Quigley Corporation.

ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

ProPhase Labs Inc.
ProPhase Labs Inc. logo
Country United States
IPO Date Apr 4, 1994
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 96
CEO Ted William Karkus

Contact Details

Address:
711 Stewart Avenue
Garden City, New York
United States
Website https://www.prophaselabs.com

Stock Details

Ticker Symbol PRPH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000868278
CUSIP Number 74345W108
ISIN Number US74345W1080
Employer ID 23-2577138
SIC Code 2834

Key Executives

Name Position
Ted William Karkus Chairman & Chief Executive Officer
Stu Hollenshead Chief Operating Officer
Jason Karkus President of Nebula Genomics
Kamal Obbad Senior Vice President and Director of Sales & Marketing - Nebula Genomics
Lance Bisesar Corporate Controller

Latest SEC Filings

Date Type Title
Aug 28, 2025 8-K Current Report
Aug 19, 2025 DEFA14A Filing
Aug 19, 2025 8-K Current Report
Aug 15, 2025 DEF 14A Filing
Aug 13, 2025 10-Q Quarterly Report
Aug 13, 2025 8-K Current Report
Aug 08, 2025 PRER14A Filing
Aug 06, 2025 8-K Current Report
Aug 05, 2025 D Filing
Jul 29, 2025 8-K Current Report